Hims & Hers Health (NYSE:HIMS) Shares Up 2.7%

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price shot up 2.7% during mid-day trading on Wednesday . The stock traded as high as $25.74 and last traded at $24.79. 11,898,449 shares traded hands during mid-day trading, a decline of 0% from the average session volume of 11,912,538 shares. The stock had previously closed at $24.15.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HIMS. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their price target for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Guggenheim raised their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a report on Tuesday, May 7th. Finally, SVB Leerink assumed coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average price target of $16.43.

Hims & Hers Health Price Performance

The stock has a market capitalization of $4.81 billion, a P/E ratio of -2,239.00 and a beta of 1.08. The business’s 50 day simple moving average is $16.38 and its 200-day simple moving average is $12.89.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,502 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $17.33, for a total transaction of $43,359.66. Following the sale, the insider now directly owns 156,855 shares in the company, valued at $2,718,297.15. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO Oluyemi Okupe sold 98,635 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $21.42, for a total transaction of $2,112,761.70. Following the sale, the chief financial officer now directly owns 146,839 shares in the company, valued at $3,145,291.38. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,502 shares of Hims & Hers Health stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $17.33, for a total transaction of $43,359.66. Following the completion of the sale, the insider now owns 156,855 shares in the company, valued at $2,718,297.15. The disclosure for this sale can be found here. Insiders have sold a total of 880,687 shares of company stock worth $15,057,669 over the last ninety days. Company insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at $48,000. Belpointe Asset Management LLC bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $76,000. Certuity LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $109,000. Corton Capital Inc. bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $122,000. Finally, Custom Index Systems LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $132,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.